Fludrocortisone for the treatment of heparin-induced hyperkalemia

Annals of Pharmacotherapy

Volumn 34, Issue 5, 2000, Pages 606-610

  Sherman, Deb S ^a   Kass, Carrie L ^b   Fish, Douglas N ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Fludrocortisone; Heparin; Hyperkalemia

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; FLUDROCORTISONE; HEPARIN; POTASSIUM;

ACUTE KIDNEY FAILURE; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CLINICAL TRIAL; HEPARINIZATION; HUMAN; HYPERKALEMIA; KALIURESIS; KIDNEY DISTAL TUBULE; MALE; MEDICAL INFORMATION; MEDICAL LITERATURE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RECEPTOR AFFINITY; SUBCLAVIAN VEIN; VEIN THROMBOSIS; ZONA GLOMERULOSA;

EID: 0034093989     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19326     Document Type: Article

References (20)

1. Tolstoi LG. Drug-induced hyperkalemia. Hosp Pharm 1996;31:221-8.
2. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98:575-86.
3. Aull L, Chao H, Coy K. Heparin-induced hyperkalemia. DICP 1990;24: 244-6.
4. Durand D, Ader JL, Rey JP, Tran-Van T, Lloveras JJ, Bernadet P, et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int 1988;34(suppl 25):S196-7.
5. Edes T, Sunderrajan EV. Heparin-induced hyperkalemia. Arch Intern Med 1985;145:1070-2.
6. Edes TE. Heparin-induced hyperkalemia. Postgrad Med 1990;87:104-5.
7. Leehey D, Gantt C, Lim V. Heparin-induced hypoaldosteronism. JAMA 1981;246:2189-90.
8. Wilson ID, Goetz FC. Selective hypoaldosteronism after prolonged heparin administration. Am J Med 1964;36:635-40.
9. Package insert. Heparin sodium. Cherry Hill, NJ: Elkins-Sinn, September 1997.
10. Gonzalez-Martin G, Diaz-Molinas MS, Martinez AM, Ortiz M. Heparin-induced hyperkalemia: a prospective study. Int J Clin Pharmacol Ther Toxicol 1991;29:446-50.
11. Conn JW, Rovner DR, Cohen EL, Andersen JE. Inhibition by heparinoid of aldosterone biosynthesis in man. J Clin Endocrinol 1966;26:527-32.
12. O'Kelley R, Magee F, McKenna TJ. Routine heparin therapy inhibits aldosterone production. J Clin Endocrinol Metab 1983;56:108-12.
13. Siebels M, Andrassy K, Vecsei P, Seelig HP, Back T, Nawroth P, et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res 1992;66:467-73.
14. Jungmann E, Schifferdecker E, Rumelin A, Althogg PH, Schoffling K. Plasma renin activity and aldosterone behavior in critically ill patients. Klin Wochenschr 1987;65:87-91.
15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Singhal PC, Desroches L, Mattana J, Abramovici M, Wagner JD, Maesaka JK. Mineralocorticoid therapy lowers serum potassium in patients with end-stage renal disease. Am J Nephrol 1993;13:138-41.
17. Package insert. Florinef (fludrocortisone acetate). Princeton, NJ: Apothecon, January 1996.
18. Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol 1989; 37:415-8.
19. Greenberg A. Hyperkalemia: treatment options. Semin Nephrol 1998;18: 46-57.
20. Hottelart C, Achard JM, Moriniere P, Zoghbi F, Dieval J, Fournier A. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs 1998;22:614-7.